Possible Interaction: Vitamin K and Sorafenib

“Dosing vitamin K could augment the anticancer action of sorafenib against HCC.”

“The previous retrospective study suggested that dosing vitamin K may enhance the anticancer action of sorafenib against hepatocellular carcinoma.”

“More importantly, vitamin K1 reduced stiffness‐dependent residual HCC cell proliferation by inhibiting ERK phosphorylation and suppressed the in vivo tumor growth, which was further enhanced by combining with sorafenib.”

“ Vitamin K1 plus sorafenib can reverse this protumor effect.”

“ConclusionsOur results indicate that modulation of the efficacy of Sorafenib through combinations with VK1 and/or IGF1-R antagonists results in synergistic inhibition of HCC cell migration.”

“PurposeEmerging evidence indicates that combining Sorafenib with vitamin K1 (VK1) may result in a synergistic inhibition of hepatocellular carcinoma (HCC) cell migration and proliferation.”

“Anti-angiogenic effects of sorafenib lead to impairment of vitamin K uptake and induction of des-γ-carboxyprothrombin release by hepatocellular carcinoma (HCC) cells.”

“HGF-stimulated HepG2 cells, which were treated with a combination of sorafenib and vitamin K , showed significantly increased expression of E-cadherin and impairment of migration ability compared to when treated with either agent alone.”

“Our experimental study demonstrated that sorafenib and vitamin K can function synergistically to inhibit the migration and proliferation of HCC cells.”

“ConclusionsOur findings indicated that VK1 enhanced the cytotoxicity effect of sorafenib through inhibiting the Raf/MEK/ERK signaling pathway in glioma cells, and suggested that sorafenib in combination with VK1 maybe a new therapeutic option for patients with gliomas.”

“ Vitamin K1 plus Sorafenib combination also resulted in elevated levels of activated c‐Jun N‐terminal kinase (JNK) and its substrates c‐Jun and FasL. JNK inhibition partly antagonized the induction of apoptosis.”

“CONCLUSIONS: Our results determined that combined treatment with sorafenib and vitamin K2 can work synergistically to inhibit the growth of hepatocellular carcinoma cells.”

“Moreover, the combination of sorafenib and vitamin K2 significantly inhibited the growth of hepatocellular carcinoma xenografts in nude mice.”

“RESULTS: Assays for 3-(4,5-dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide) revealed a strong synergistic growth-inhibitory effect between sorafenib and vitamin K2.”

“ Vitamin K2 also attenuated the downregulation of p21 expression induced by sorafenib , which may represent the mechanism by which vitamin K2 promotes the inhibitory effects of sorafenib on cell proliferation.”

“A Raf kinase activity assay confirmed that combination vitamin K1 plus sorafenib had a synergistic inhibitory effect on it.”

“We found that whereas lower concentration of vitamin K1 (25 μM) or sorafenib (2.5 μM) alone slightly induced c-Raf phosphorylation at both Ser-43 and Ser-259, combination vitamin K1 plus sorafenib resulted in strong c-Raf phosphorylation at these two serine residues.”

“Background: Some researchers have suggested that vitamin K enhances the antitumor effect of sorafenib for hepatocellular carcinoma (HCC) in vitro and in vivo.”